Governments should pay for smoking cessation therapies: Canadian researchers

Aug 30, 2010

Canada should follow the lead of Quebec, Australia and the United Kingdom by publicly funding smoking cessation pharmacotherapies, states an editorial in CMAJ (Canadian Medical Association Journal).

Some 5.5 million Canadians (19% of the population) currently use tobacco, a number that has not decreased in recent years. A 2009 review of studies indicates that full financial reimbursement of smoking cessation medications significantly improves one-year abstinence rates among all smokers. And those who quit live, on average, an additional four years. Fully funding these tools in Canada could result in a gain of 1.9 million life-years, at a cost of $220 for every life-year gained, which is a bargain compared with other health interventions.

Currently, only Quebec publicly funds all smoking cessation pharmacotherapies, and only the Yukon and Prince Edward Island reimburse for at least one product. In Australia and the United Kingdom reimbursement is available without restriction for all products, including prescription medications and over-the-counter . In the United States, these products are reimbursed by Veterans Affairs and Part D Medicare.

The editorial writers propose immediately including smoking cessation therapies in all provincial drug formularies so that smokers over the age of 65 and those receiving social assistance can have free access. Then "follow the lead of other countries and reimburse therapies for everyone," write Erika D. Penz and Braden J. Manns of the University of Calgary, Dr. Matthew B. Stanbrook, Deputy Editor Scientific and Dr. Paul Hebert, Editor-in-Chief. "An appropriate source of funding for this is obvious: the substantial tax revenues collected with the sale of every tobacco product."

Explore further: Young girl's story may lead Idaho to approve marijuana oil

More information: www.cmaj.ca/cgi/doi/10.1503/cmaj.101140

add to favorites email to friend print save as pdf

Related Stories

Smoking cessation therapies more effective than placebos

Jul 14, 2008

Six treatments for smoking cessation perform better than placebos — including varenicline (Chantix®), recently approved for use in Canada — states a team of researchers from McGill University and the University of Montreal ...

Not ready to quit? Try cutting back

Dec 07, 2006

In a review article in the December Nicotine and Tobacco Research, researchers at the University of Vermont have found an unexpected, effective alternative to motivate smokers to quit smoking – cutting back. According to ...

Recommended for you

Young girl's story may lead Idaho to approve marijuana oil

3 hours ago

(AP)—Ten-year-old Alexis Carey has a rare but intractable form of epilepsy, Dravet Syndrome. The genetic diseases causes severe and multiple seizures, which often leave parents guessing if the terror of watching their child ...

Psychology of food choice: Challenging the status quo

10 hours ago

Researchers are challenging conventional beliefs about the effectiveness of traditional strategies for encouraging healthy eating. The symposium, "Challenging Misconceptions About the Psychology of Food Choice," includes ...

Crohn's disease not exempt from racial disparities

Feb 27, 2015

A study published recently in the IBD Journal found significant differences in hospital readmissions, medication usage, and both medical and surgical complications of children with Crohn's disease related to race. In the ...

User comments : 0

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.